The new facility will enable NTD to meet increased demand for advanced prenatal screening technology including the Ultra-Screen® free Beta hCG/PAPP-A/NT Down syndrome screen and other prenatal screening and diagnostics as PerkinElmer continues to expand its maternal healthcare offerings. The New York Department of Health certified facility will also include a maternal sample bank.
“The Melville facility was designed to meet growing demand for advanced prenatal monitoring technologies, expanded capacity for analytical services and R&D, and expanded maternal health services,” said Ann-Christine Sundell, president, Genetic Screening, PerkinElmer. “For example, NTD will have the capability to translate research in pre-eclampsia to expand maternal health.”
Sundell noted that the 22,000-square-foot facility will include an information technology system based on the company’s highly successful Specimen Gate® LIMS software used in many U.S. state laboratories to handle several hundred thousand bloodspot samples.
For more information, visit www.ntdlabs.com.
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has approximately 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
